Folfirinox gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score study.

Date publication

janvier 2019

Journal

Therapeutic advances in gastroenterology

Auteurs

Membres identifiés du Cancéropôle Est :
Mme POZET Astrid

Tous les auteurs :
Williet N, Saint A, Pointet AL, Tougeron D, Pernot S, Pozet A, Bechade D, Trouilloud I, Lourenco N, Hautefeuille V, Locher C, Desrame J, Artru P, Thirot Bidault A, Le Roy B, Pezet D, Phelip JM, Taieb J

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/31598136

Résumé

Folfirinox (FFX) and gemcitabine/nab-paclitaxel (GN) are both standard first-line treatments in patients with metastatic pancreatic cancer (mPC). However, data comparing these two chemotherapeutic regimens and their sequential use remain scarce.

Mots clés

Folfirinox, gemcitabine/nab-paclitaxel, metastatic, pancreatic adenocarcinoma, survival

Référence

Therap Adv Gastroenterol. 2019 ;12:1756284819878660